Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FA01 Rituximab
D02994 Rituximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Rituximab
D02994 Rituximab (USAN/INN)
Immunological Agents
Immunosuppressants
Immunosupressants, Other
Rituximab
D02994 Rituximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D02994 Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D02994 Rituximab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02994
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02994
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02994
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D02994